Search Results

By Matthew Stenger  / Friday, September 13, 2013 1:06 PM

Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma

Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...